Key points from article :
A woman in Wales has been given the all-clear from stage three bowel cancer after being treated with the drug dostarlimab.
Dostarlimab is a new drug that works by helping the immune system to destroy the cancer.
It is administered every three weeks for six months; side effects are minimal or non-existent.
It is still being clinically trialled, but early data has shown a 100% success rate against a specific variant of bowel cancer.
All 36 U.S. bowel cancer patients in an early phase trial had no detectable cancer after treating with dostarlimab.
Wales is the first UK nation to have dostarlimab approved as a standard treatment offer.
Two Welsh women have been successfully treated with dostarlimab so far.
Study conducted at Swansea Bay University.
